Form 4: HeartBeam Director Boosts Stake, Receives Equity Awards

HeartBeam Director Willem Elfrink reported an increase in his beneficial ownership through direct stock holdings, indirect trust holdings, and new equity awards including restricted stock units and stock options.

Summary

• Willem Elfrink, a Director of HeartBeam, Inc. (BEAT), reported changes in his beneficial ownership.
• He directly owns 351,167 shares of Common Stock.
• An additional 106,825 shares of Common Stock are held indirectly through the Elfrink Living Trust, where he serves as trustee.
• Mr. Elfrink was granted 60,483 Restricted Stock Units (RSUs) on July 11, 2025, which will vest 100% on the earlier of July 11, 2026, or the Issuer's 2026 annual meeting of stockholders, subject to continued service.
• He was also granted options to purchase 45,454 shares of Common Stock on September 30, 2025, with an exercise price of $1.65 per share and an expiration date of July 1, 2035.
• These options vest in two tranches: one half on the three-month anniversary of the July 1, 2025 vesting commencement date, and the remaining half on the six-month anniversary.
• Following these transactions, Mr. Elfrink beneficially owns a total of 457,992 shares of Common Stock (direct and indirect), 60,483 RSUs, and 89,090 Common Stock options.

Sentiment

Score: 7

Explanation: The filing indicates a director's increased beneficial ownership and receipt of equity awards, which generally aligns management's interests with shareholders and can be viewed positively by the market as a sign of confidence.

Positives

• A Director increasing their beneficial ownership through equity awards and direct holdings generally signals confidence in the company's future prospects.
• The granting of Restricted Stock Units (RSUs) and stock options aligns the Director's long-term interests with those of the shareholders, as vesting is tied to continued service and potential stock price appreciation.

Risks

• The value of the equity awards (RSUs and options) is subject to the future performance of HeartBeam's common stock, which carries inherent market risks.
• Vesting of RSUs and options is contingent upon the reporting person continuing to serve as an Outside Director through the specified vesting dates.

Future Outlook

The filing indicates future vesting events for Restricted Stock Units (RSUs) on the earlier of July 11, 2026, or the 2026 annual meeting, and for stock options over a six-month period following a July 1, 2025 vesting commencement date. These events are contingent on the Director's continued service.

Industry Context

This Form 4 filing is a standard disclosure of insider trading activity and does not provide broader industry context or trends. It reflects an individual director's equity compensation and investment in the company.

Corporate Governance

Related Party Transactions

• 106,825 shares of Common Stock are held indirectly by the Elfrink Living Trust, of which the reporting person, Willem Elfrink, is the trustee.

Stakeholder Impact

• Shareholders: Increased alignment of a director's financial interests with shareholder value through direct holdings and performance-based equity awards.
• Management/Employees: The equity awards serve as compensation and retention incentives for the Outside Director.

Next Steps

• Vesting of 60,483 Restricted Stock Units (RSUs) on the earlier of July 11, 2026, or the Issuer's 2026 annual meeting of stockholders.
• Vesting of common stock options: one half on the three-month anniversary of July 1, 2025, and the remaining half on the six-month anniversary.

Key Dates

Keywords

HeartBeam, BEAT, Form 4, Insider Transaction, Director, Equity Awards, Restricted Stock Units, Stock Options, Beneficial Ownership, Corporate Governance